Close Menu

NEW YORK (GenomeWeb News) – Saladax Biomedical today said that it will offer its My5-FU assay as part of its MyCare service offering later this year after regaining marketing rights to the test from Myriad Genetics.

The Bethlehem, Pa.-based firm said that it would begin offering the assay, which is used to help guide optimized dosing of infusional 5-fluorouracil to patients, later this year when its CLIA lab commences operations in June. 5-FU is used to treat several types of cancers.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new study catalogues the genome and evolutionary history of the oak family, UPI reports.

Dog DNA testing is a growing market, but there's still a lot of uncertainty about the accuracy of the results, the Boston Globe says.

A University of South Florida researcher is testing bone fragments to determine if they belong to Amelia Earhart.

In Cell this week: antisense Piwi-interacting RNA responses to endogenous retroviruses, proteomic patterns in hepatocellular carcinoma, and more.

Oct
21
Sponsored by
Agilent

Genomics is a key element in the potential of precision medicine to transform oncology. 

Oct
23
Sponsored by
Swift Biosciences

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.